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Summary
Aims: Characterization of breast câncer patients with micrometastases in sentinel lymph node (SLN) and establish differences
between micrometastatic breast cancers with additional metastatic lymph nodes (LNS) versus no other lymph node invasion.
Methods: Analysis of 30 breast cancers, Nlmi or pNO(i+), diagnosed and treated in our department from July 2000 to July 2008.
Results: Micrometastases in SLNs were found in 30 patients. Complete axillary dissection revealed other metastatic LNs in 24%.
Concerning breast cancers with additional LN invasion versus no other LN invasion, tumors located in the superior-external quad-
rant were more frequent in the former group. Other characteristics as clinicai presentation, histological subtype, focality, cytonu-
clear grade, hormone receptors and Her2 expression were not significantly different in either group. Regarding SLN invasion, the
presence of at least two micrometastatic foci were significantly more relevant in patients with other metastatic LN invasion (p <
0.01). Micrometastases diagnosed only after immunohistochemistry (IHC) were exclusively found in patients without other LN inva-
sion, reaching statistical significance (p < 0.05). Conclusions: Complete axillary dissection revealed additional LN invasion in 24%
of patients with micrometastases in the SLN. Tumors with additional LN invasion were more frequently found in the superior exter-
nai quadrant and SLNs harbored at least two micrometastatic foci. Micrometastases diagnosed exclusively by IHC techniques were
more relevant in cases without additional lymph node invasion.
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Introduction
Lymph node (LN) metastases are considered the most
important prognostic factor in breast câncer patients [1,2].
Axillary LN status is determined after histological exami-
nation of at least ten LNs are surgically removed [3]. Axil-
lary dissection was first considered a therapeutic interven-
tion to eliminate disease from regional LNs [4]. It later
became the only surgical staging procedure available [5].
With the advancement of sentinel lymph node (SLN)
biopsy in early breast cancers (TO-T2, NO), this same
Information can be obtained by removal of only a few
nodes, avoiding much of the morbidity associated with
axillary dissection [6]. Histopathologic examination of
SLNs is more detailed than traditional examination of axil-
lary nodes [1,2]. Further axillary surgery depends on SLN
status. Serial sectioning of SLNs and use of immunohisto-
chemistry (IHC) with cytokeratin have led to increased
detection of minimal lymph node involvement, classified
as micrometastases (0.2-2 mm; pNl (mi)) and isolated
tumor cells (ITCs) (< 0.2 mm; pNO(i+)) [1,7].
After detection of micrometastases that the SLN hás
incorporated into its staging system, many breast tumors
become upstaged [8]. The significance of micrometas-
tases remains controversial. Value of complete axillary
dissection after finding micrometastases is still not uni-
formly defined. It would be of great value to identify a
guide for estimating risk of non SLN involvement.
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The aims of this study were to identify parameters
more associated with other LN involvement in breast
câncer patients with micrometastases in SLN. We also
intended to characterize breast cancers with micrometas-
tases in SLN and prevalence of additional metastatic
invasion after axillary dissection.
Methods
Analysis of 30 breast câncer patients with micrometastases in
SLNs diagnosed in our department from July 2000 to July 2008
was carried out.
In breast cancers (TO-T2) with clinicai and imaging negative
axillary nodes, SLN biopsy is performed using a blue dye tech-
nique.
Twenty-five patients with micrometastatic SLNs were sub-
mitted to axillary dissection. Clinicai and histological parame-
ters were compared in cases with other metastatic LNs versus
no other metastatic LNs besides micrometastatic SLN.
The analytic data included patient characteristics (age, hor-
monal status) and clinicai characteristics (presentation, loca-
tion). Histopathological data studied breast tumor histological
type, size, cytonuclear (Bloom Richardson) grade, focality and
hormone (estrogen and progesterone) receptors. SLN was his-
tologically analyzed after serial section (100 p.m thickness)
using classical staining - hematoxylin and eosin (H&E) and
IHC (MNF116) when classic staining was negative or inconclu-
sive. Lymph nodes obtained from later axillary dissection were
studied to identify additional invasion.
Descriptive statistics are reported as frequencies, percent-
ages, means and Standard deviations. Distribution of categorical
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variables were compared using the chi-square test. Parametric
variables were tested using Student's t-test. Statistical analysis
was performed using SPSS version 15.0.
Results
Micrometastases in SLNs were found in 30 patients.
Mean age was 55.2 ± 12.0 (40-81) and 50% post-
menopausal with a mean menopausal age of 50.7 ±3.1
(45-56). Tumors presented clinically as palpable lesions
in 22 cases (74%). The remaining patients showed image
(mammography or mammary ultrasound) alterations (n =
8). Lesions were described in the following quadrants:
superior-external in 60% (n = 18), superior-internal in
20% (n - 6), inferior-internal in 10% (n = 3), inferior
externai in 3% (n = 1) and retroareolar in 7% (n = 2). His-
tology revealed mainly ductal invasive carcinoma (n =
26) but also two invasive lobular carcinomas and another
two mucinous invasive carcinomas were reported. Multi-
focal lesions were found in 21%. Tumors were pTl in 25
cases (83%) and pT2 in five cases (17%). Concerning
cytonuclear grade, G2 tumors were found in 73% (n -
22) and Gl (n = 4) and G3 (n = 4) tumors in 13% each.
Lymphovascular invasion was present in four tumors
(13%). Estrogen receptors (ERs) were positive in 97% (n
= 29). Progesterone receptors (PRs) were positive in 68%
(n = 17) and negative in 32% (n = 8). Cerb2 was positive
in 21% (n = 6) and negative in 89% (n = 22).
Micrometastases in SLN measured between 0.2-2 mm
in 27 patients. In the remaining three cases ITCs were
found (z 0.2 mm). Considering the focality of
micrometastases in SLNs, 25 were related only to one
focus and in the other five at least two foci were noted.
Diagnosis of micrometastases was performed using H&E
in 23 cases and IHC in the seven cases with negative stan-
dard staining.
Completion of axillary dissection was performed in 25
patients after SLN analysis. On average 13.9 LNs were
removed. Six patients (24%) had additional metastatic
invasion revealed by axillary dissection, including two
(8%) macrometastases (a 2 mm) and four (16%)
micrometastases (< 2 mm). Additional micrometastatic
LNs harbored one focus in two cases (8%) and two foci
in another two cases (8%). Table l summarizes the com-
parison between tumors with SLN micrometastases with
additional metastases versus without other metastatic
LNs reported in axillary dissection. Significant differ-
ences were found considering the presence of tumors in
the superior-external quadrant. Table 2 correlates the
number of micrometastatic foci and additional LN inva-
sion. The presence of at least two micrometastatic foci in
SLN was more frequent in patients with other metastatic
LNs. Table 3 compares the method of detecting
micrometastases and implications considering other LN
invasion. Diagnosis of micrometastases by IHC (negative
H&E) was more associated in patients without other
metastatic LNs, reaching Statistical significance (p <
0.05).
Table 1. — Comparison between micrometastatic tumors
without additional LN invasion v s with additional LN invasion.
(LN: lymph node; SLN: sentinel lymph node; n.s.: non-
significant; IDC: invasive ductal carcinoma; ILC: invasive
lobular carcinoma; IMC: invasive mucinous carcinoma; DC1S:
ductal carcinoma in-situ; ER: estrogens receptor; PR:
progesterone receptor).
Micrometastases in SLN
Other LN invasion Without LN invasion p value



















































































Table 2. — Number of micrometastatic foci and correlation
with LN invasion. (LN: lymph node; SLN: sentinel lymph
node).
Micrometastases in SLN
Other LN invasion Without LN invasion p value
n = 6 n = 19
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Table 3. — Method of detecting micrometastases in SLNs and
correlation with presence of additional LN invasion. (SLN:
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Discussion
SLN biopsy aims to allow a correct staging procedure,
avoiding the need of complete axillary dissection in cases
without SLN invasion. A meticulous pathologic study is
performed in SLNs, detecting the presence of metastatic
disease as small as 0.2 mm.
In this series, in face of micrometastases in SLNs, we
found an incidence of 24% additional LN invasion.
Several studies suggested that presence of micrometas-
tases in SLNs correlates with absence of metastases in
non-sentinel LNs [8, 9]. Langer et ai. reported in a
prospective trial that SLN micrometastases do not harbor
risk of axillary recurrence or distant disease [11]. This
emphasizes the idea of avoiding further axillary dissec-
tions. In contrast, other investigators suggested a relevant
percentage of non-SLN involvement in micrometastatic
SLNs [12, 13], reaching 26% [14]. A recent meta-analy-
sis reported the risk of non-SLN metastases associated
with micrometastatic disease in SLNs of around 10-15%,
depending on the method of detecting SLNs [15].
The greatest aim with a micrometastatic SLN is to
identify patients at risk of additional LN invasion. Con-
sidering patients submitted to complete axillary dissec-
tion (n = 25), we compared clinicai and histological
parameters between tumors with other LN invasion (n =
6) and those without other LN invasion (n = 19). We eval-
uated, tumor characteristics, hormonal stage, clinicai
presentation, location (quadrant), histological subtype,
focality, DCIS associated, cytonuclear grade, stage, hor-
monal receptors (ER, PR) and Her2 expression. Signifi-
cant differences between breast cancers with other
metastatic invasion besides the SLN were related to
primary tumor location, with the superior-external quad-
rant being significantly more associated with additional
invasion. Other parameters were not significantly differ-
ent (Table 1).
Some previous studies have emphasized the role of
some tumor aspects, as tumor size and lymphovascular
invasion, as predictive factors for the presence of
metastatic LNs [8, 16]. In a multicentric study predictive
factors were pT stage, menopausal status, grade, lympho-
vascular invasion and histological type [17]. One study
reported micrometastases from invasive lobular carci-
noma was related with other LN involvement; on the con-
trary ali invasive ductal carcinomas had negative axillary
dissection [18].
Our results emphasize the location of the primary
tumor as the only predictive factor, considering primary
tumor characteristics for additional LN invasion. Lymph
flows unidirectionally from the superficial to deep plexus
and from the de subareolar plexus through the lymphatic
vessels of the lactiferous ducts to the perilobular and deep
subcutaneous plexus [19]. Intramammary lymphatic
vessels move centrifugally toward axillary and internai
mammary lymph nodes [19]. With this drainage system
in mind, it seems logical that tumors located in the supe-
rior externai quadrant originate more frequently from
small metastatic foci in the axillary lymph nodes. In con-
sonance with the centrifugal movement in lymphatic
vessels, metastases from tumors with this topographic
location flow a shorter way toward the axilla.
Focusing on SLN analysis, the presence of at least two
micrometastatic foci was significantly more associated
with additional axillary invasion. It hás been reported that
risk of non-SLN metastasis is related to the size of
disease in SLNs [l, 20], being the greatest for
macrometastases, intermediate for micrometastases, and
the least for ITCs (14.8%), more frequently detected by
IHC [21]. Besides classical H&E, the advent of IHC
directed to cytoqueratin can identify up to 34% initially
negative SLNs [22, 23]. With IHC we could identify
more (7/30) micrometastatic SLNs. In our study,
micrometastases detected by IHC were not associated
with additional metastatic invasion besides the SLN,
reaching statistical significance. These results emphasize
the idea that SLN metastases diagnosed by routine H&E
have a higher risk of non-SLN metastases than metas-
tases detected by IHC, reflecting a larger metastatic size
in the former group [24]. Studies confirm the increase
incidence in the detection of micrometastases by IHC [ l,
17, 21]. The prospective use of IHC by Rydén et ai. only
showed stage migration in 3/132 cases [1]. Ali these
reports supports the idea that patients with micrometas-
tases detected by IHC have a low risk of additional LN
invasion.
Controversy exists surrounding the best management
of patients with SLN micrometastases. In approximately
80% of patients with SLN micrometastases, the SLN is
the only LN involved [20]. These particular patients
would not benefit from further axillary surgery. Recent
studies report that selected patients with micrometastases
without further axillary dissection will not suffer from a
higher incidence of regional recurrence [25, 26].
Various studies suggest that the prognosis of breast
câncer patients with micrometastases should not be con-
sidered the same as that of truly node-negative patients
(pNO), with a poorer survival for micrometastatic patients
[27, 28]. This means that minimal LN invasion cannot be
safely overlooked, particularly when tumors are located
in the superior-external quadrant and SLN harbors at
least two micrometastatic foci, as we proved in our
results. This is the only possible way to solve this
problem - the Identification of predictive factors associ-
ated with LN invasion besides SLN micrometastases. The
real clinicai impact of micrometastases will only be
assured after results of on-going randomized controlled
trials are known [29, 30].
Conclusions
In this study the incidence of additional LN invasion in
face of micrometastatic SLNs was 24%. Primary tumor
characteristics predictive of other metastatic involvement
besides SLNs was the superior-external quadrant loca-
tion, reaching statistical significance. Other parameters
like hormone stage, clinicai presentation, histological
type, focality, cytonuclear grade, hormone receptors and
Her2 expression were not significantly different. Consid-
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ering analyzes of SLN, the presence of at least two
metastatic SLN foci was significantly more frequent in
patients with additional LN invasion. Finally, micrometas-
tases detected by IHC with negative H&E were exclu-
sively reported in patients without other LN invasion,
also statistically significant.
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